Among the most recent ones, urinary tissue inhibitor of metalloproteinases-2 (TIMP-2) and insulin-like growth factor binding protein 7 (IGFBP7) product have been proven to be a good predictor of AKI [5] and received FDA approval for AKI risk assessment in critically ill patients. The gene discussed is IGFBP7; the disease is acute kidney injury.